MNG1162
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.297
- COAGULATION+0.286
- KRAS_SIGNALING_DN+0.279
- MYOGENESIS+0.233
- PANCREAS_BETA_CELLS+0.222
- SPERMATOGENESIS+0.165
- APICAL_JUNCTION+0.140
- ESTROGEN_RESPONSE_LATE+0.114
- APICAL_SURFACE+0.085
- XENOBIOTIC_METABOLISM+0.002
Top 10 suppressed
- PROTEIN_SECRETION-0.566
- MYC_TARGETS_V1-0.452
- ANDROGEN_RESPONSE-0.445
- MTORC1_SIGNALING-0.432
- UNFOLDED_PROTEIN_RESPONSE-0.430
- TNFA_SIGNALING_VIA_NFKB-0.417
- MYC_TARGETS_V2-0.336
- TGF_BETA_SIGNALING-0.327
- UV_RESPONSE_DN-0.313
- CHOLESTEROL_HOMEOSTASIS-0.302
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD035_R.RNA-Seq | EPN | Posterior Fossa EPN | 0.887 |
| 2 | MNG1137 | — | — | 0.882 |
| 3 | SRR1472663 | GTEX | — | 0.881 |
| 4 | MNG1158 | — | — | 0.879 |
| 5 | SRR1451964 | GTEX | — | 0.872 |
| 6 | SRR1348861 | GTEX | — | 0.869 |
| 7 | SRR1360674 | GTEX | — | 0.866 |
| 8 | SRR1500405 | GTEX | — | 0.864 |
| 9 | SRR1332048 | GTEX | — | 0.863 |
| 10 | SRR1479759 | GTEX | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.297 | Inavolisib | — uncovered |
| COAGULATION | 0.286 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.279 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.233 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.222 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.165 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.114 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.085 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.002 | Inavolisib | — uncovered |